Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 10/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.44 |
| ▸ | FPR2 | P25090 | 4/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613183 | 0.76 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DREN | |
| SCHEMBL19252770 | 0.76 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DREN | |
| SCHEMBL19259542 | 0.76 | PDE4A (0.39) | PDE4APDE4BPDE4CPDE4DHIF1A | |
| SCHEMBL19272933 | 0.74 | PDE4B (0.34) | PDE4APDE4BPDE4CPDE4DHIF1A | |
| SCHEMBL29613157 | 0.73 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DREN | |
| SCHEMBL28767997 | 0.73 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DHIF1A | |
| SCHEMBL19252809 | 0.73 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DREN | |
| SCHEMBL19273110 | 0.72 | KDM1A (0.42) | PDE4APDE4BPDE4CPDE4DREN | |
| SCHEMBL19252773 | 0.71 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DHIF1A | |
| SCHEMBL29613142 | 0.71 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416946-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | Novartis AG (CH) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017140821-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2017-08-24 | — | — | WO | disclosed |
| US-20170240548-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240548-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | PNPO, HAVCR2, TYMP | PDE4A 2146/4885PDE4B 1845/4885PDE4C 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.